Pre-made Imdevimab benchmark antibody ( Whole mAb, anti-SARS-CoV-2 Spike RBD therapeutic antibody) for drug discovery and mechanism of action (MOA) researchCat No.: GMP-Bios-ab-267
Pre-Made Imdevimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Casirivimab/imdevimab, sold under the brand name REGEN-COV, is an experimental medicine developed by the American biotechnology company Regeneron Pharmaceuticals. It is an artificial "antibody cocktail" designed to produce resistance against the SARS-CoV-2 coronavirus responsible for the COVID-19 pandemic. It consists of two monoclonal antibodies, casirivimab (REGN10933) and imdevimab (REGN10987) that must be mixed together. The combination of two antibodies is intended to prevent mutational escape. It is also available as a co-formulated product.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|List Price(In USD)
Size： 1mg | 10mg | 100mg
|Products Name (INN Index)
|Pre-Made Imdevimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody
|SARS-CoV-2 Spike RBD
|Highest_Clin_Trial (Jan '20)
|100% SI Structure
|99% SI Structure
|95-98% SI Structure